WGNO

Radius Health's TYMLOS® (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture

Osteoporosis-related fractures are an important health concern because of related morbidity, mortality, and cost. 2 Bruce Mitlak, M.D., the Chief Medical Officer of Radius, emphasized that "30% of all ...
Nasdaq

Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal

Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...
WKRG

Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

"The real-world data presented further supports the favorable efficacy and safety profile of TYMLOS and why it is an important treatment option in the management of osteoporosis," said Dr. Felicia ...
AOL

Is Tymlos covered by Medicare?

Tymlos (abaloparatide) is a brand-name injectable medication used to treat osteoporosis. Medicare may cover Tymlos, but coverage and cost depend on the specifics of a person’s plan and how they ...
BioWorld

FDA clears Radius osteoporosis therapy Tymlos; Lilly's Forteo in crosshairs

Radius Health Inc. won FDA approval, albeit mildly delayed, of injected Tymlos (abaloparatide) for postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic ...